45 completed. 45 Phase 2, 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Completed 45 |
| Phase 1 | 13 | Completed 13 |
Follow Recurrent Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Marginal Zone Lymphoma trials Research Report on Recurrent Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| A Phase I/II Study of Intratumoral Injection of SD-101 Ipilimumab, SD-101, Radiation therapy - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 9 | 2014-09-01 | 2019-11-27 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Fludarabine, Busulfan, Total Body Irradiation (TBI) - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 40 | 2011-08-04 | 2026-04-15 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2011-07-20 | 2021-10-04 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma bendamustine hydrochloride, dexamethasone, filgrastim - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | University of Washington | 43 | 2010-08-01 | 2017-05-24 |
| Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Temsirolimus - AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 110 | 2010-04-15 | 2019-10-16 |
| Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma panobinostat, everolimus, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 124 | 2009-06-01 | 2020-03-10 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 63 | 2009-02-01 | 2018-01-02 |
Showing 20 of 45. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (45) · Lymphoma, Follicular (45) · Leukemia, Lymphocytic, Chronic, B-Cell (39) · Lymphoma, Mantle-Cell (36) · Lymphoma, Non-Hodgkin (36) · Lymphoma, Large B-Cell, Diffuse (35) · Waldenstrom Macroglobulinemia (34) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (30) · Burkitt Lymphoma (28) · Lymphoma, Large-Cell, Immunoblastic (28) · Hodgkin Disease (26) · Lymphoma, T-Cell, Cutaneous (22) · Mycosis Fungoides (22) · Sezary Syndrome (22) · Lymphoma, Large-Cell, Anaplastic (20)
Hemic and Lymphatic Diseases (45) · Immune System Diseases (45) · Immunoproliferative Disorders (45) · Lymphatic Diseases (45) · Lymphoproliferative Disorders (45) · Neoplasms by Histologic Type (45) · Lymphoma (44) · Lymphoma, B-Cell (44) · Neoplasms (44) · Hematologic Diseases (43) · Leukemia (40) · Leukemia, Lymphoid (40) · Chronic Disease (39) · Disease Attributes (39) · Leukemia, B-Cell (39)
Mycophenolic Acid (12) · Peripheral Blood Stem Cell Transplantation (12) · Whole-Body Irradiation (12) · fludarabine phosphate (12) · Cyclosporine (10) · Rituximab (10) · Cyclophosphamide (7) · Tacrolimus (7) · Busulfan (4) · Calcium Dobesilate (4) · Dexamethasone (4) · Etoposide (4) · Methotrexate (4) · Sirolimus (4) · merphos (4)
Fred Hutchinson Cancer Center (16) · National Cancer Institute (NCI) (11) · Mayo Clinic (4) · University of Washington (3) · Case Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · David Bond, MD (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Robert Lowsky (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Chicago (1) · Wake Forest University Health Sciences (1)
United States (45) · Italy (5) · Germany (2) · Denmark (1)
Ajay Gopal (4) · Brenda Sandmaier (4) · David Maloney (4) · Anas Younes (2) · Sonali Smith (2) · Barbara Pro (1) · Brenda Cooper (1) · Brenda Cooper, MD (1) · David Bond, MD (1) · Francisco Hernandez-ILizaliturri (1) · George Chen (1) · Hillard Lazarus (1) · Hongtao Liu (1) · John Gerecitano (1) · Kami Maddocks, MD (1)
PMID 32499241, PMID 19900571, PMID 20837940, PMID 21300924, PMID 21508413, PMID 25085357, PMID 26213141, PMID 26764356, PMID 28314788, PMID 28424162, PMID 30454872, PMID 31481800, PMID 34320785, PMID 34780125, PMID 39161543
P30CA015704 (9), P01CA018029 (4), N01CM62202 (3), P01CA078902 (3), N01CM17003 (2), N01CM62201 (2), P30CA014599 (2), P30CA015083 (2), P50CA097274 (2), N01CM00039 (1), N01CM00071 (1), N01CM17101 (1), N01CM17107 (1), N01CM62203 (1), N01CM62209 (1)